Basic Information
invIOs is a privately held biotechnology company headquartered in Vienna, Austria, focusing on the discovery and development of innovative cancer immunotherapies. invIOs was spun off from APEIRON Biologics in January 2022 with the aim of developing therapies that improve and protect the lives of cancer patients. To this end, invIOs offers unique and highly promising new treatment options in the field of immunotherapy for oncology. The proactive team at invIOs possesses extensive expertise across the entire biotech value chain. invIOs is a pioneer in researching and developing cellular therapies and immunomodulatory candidates targeting novel immune checkpoints.